Your browser is no longer supported. Please, upgrade your browser.
Settings
XFOR X4 Pharmaceuticals, Inc. daily Stock Chart
XFOR [NASD]
X4 Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-18.04 Insider Own0.60% Shs Outstand12.74M Perf Week39.33%
Market Cap258.62M Forward P/E- EPS next Y-12.58 Insider Trans- Shs Float12.04M Perf Month4.53%
Income-43.00M PEG- EPS next Q-3.30 Inst Own16.20% Short Float0.72% Perf Quarter11.66%
Sales3.50M P/S73.89 EPS this Y-26.70% Inst Trans-4.93% Short Ratio2.75 Perf Half Y125.56%
Book/sh9.05 P/B2.24 EPS next Y7.50% ROA-82.60% Target Price3.00 Perf Year-78.65%
Cash/sh2.42 P/C8.40 EPS next 5Y- ROE-126.80% 52W Range6.90 - 134.58 Perf YTD45.83%
Dividend- P/FCF- EPS past 5Y- ROI-155.50% 52W High-84.84% Beta-
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low195.65% ATR2.07
Employees15 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)61.66 Volatility12.87% 10.70%
OptionableNo Debt/Eq0.37 EPS Q/Q16.50% Profit Margin- Rel Volume1.94 Prev Close20.30
ShortableYes LT Debt/Eq0.37 Earnings- Payout- Avg Volume31.67K Price20.40
Recom3.00 SMA2022.74% SMA5015.55% SMA20035.99% Volume42,187 Change0.49%
Apr-24-19 08:30AM  X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer Business Wire +6.06%
Apr-12-19 09:29AM  X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants Business Wire -16.75%
Apr-11-19 04:00PM  X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants Business Wire -8.48%
Apr-02-19 08:30AM  X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors Business Wire
Apr-01-19 08:30AM  X4 Pharmaceuticals Provides Business and Clinical Development Update Business Wire
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenstrom macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.